Sirtex invests in BlackSwan Vascular

By staff writers

December 9, 2020 -- Radiation oncology firm Sirtex Medical has made an investment in BlackSwan Vascular, a company developing therapies for endovascular embolization.

Sirtex's investment supports BlackSwan's clinical trials for BlackSwan Lava, a liquid embolic system for a peripheral vascular clinical indication. The agreement also includes an option for Sirtex to acquire BlackSwan.

If cleared by the U.S. Food and Drug Administration, the product would be the first system that optimizes radiopacity, reduces preparation time and controls delivery, and is available in two viscosities for use in the treatment of peripheral vascular diseases, according to Sirtex.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking